Therapy of childhood acute myelogenous leukemias

J Vormoor; J Boos; K Stahnke; H Jürgens; J Ritter; U Creutzig

doi:10.1007/s002770050193

Therapy of childhood acute myelogenous leukemias

J Vormoor, J Boos, K Stahnke, H Jürgens, J Ritter, U Creutzig

Research output: Contribution to journal › Review article › peer-review

Abstract

Acute myelogenous leukemia (AML) accounts for approximately 20% of acute leukemias in children. Although AML is more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), significant progress in improving outcome for AML patients has been achieved over the past 15 years. This can be attributed to intensification of chemotherapy, increased use of bone marrow transplantation, and improved supportive care. Thus 30-50% of children with AML achieve long-term event-free survival with current treatment strategies [61, 66, 85, 96]. This review gives an overview about the evolution of and rationale for current pediatric treatment protocols, with special emphasis on the German Berlin-Frankfurt-Münster (BFM) studies, and discusses new directions for the future.

Original language	English
Pages (from-to)	11-24
Number of pages	14
Journal	Annals of hematology
Volume	73
Issue number	1
DOIs	https://doi.org/10.1007/s002770050193
Publication status	Published - Jul 1996
Externally published	Yes

Keywords

Antineoplastic Agents/therapeutic use
Bone Marrow Transplantation
Central Nervous System Neoplasms/prevention & control
Child
Child, Preschool
Clinical Trials as Topic
Humans
Infant
Leukemia, Myeloid, Acute/therapy
Prognosis

Access to Document

10.1007/s002770050193

Cite this

@article{da46b823fc50497c9e0d6aed24075026,

title = "Therapy of childhood acute myelogenous leukemias",

abstract = "Acute myelogenous leukemia (AML) accounts for approximately 20% of acute leukemias in children. Although AML is more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), significant progress in improving outcome for AML patients has been achieved over the past 15 years. This can be attributed to intensification of chemotherapy, increased use of bone marrow transplantation, and improved supportive care. Thus 30-50% of children with AML achieve long-term event-free survival with current treatment strategies [61, 66, 85, 96]. This review gives an overview about the evolution of and rationale for current pediatric treatment protocols, with special emphasis on the German Berlin-Frankfurt-M{\"u}nster (BFM) studies, and discusses new directions for the future.",

keywords = "Antineoplastic Agents/therapeutic use, Bone Marrow Transplantation, Central Nervous System Neoplasms/prevention & control, Child, Child, Preschool, Clinical Trials as Topic, Humans, Infant, Leukemia, Myeloid, Acute/therapy, Prognosis",

author = "J Vormoor and J Boos and K Stahnke and H J{\"u}rgens and J Ritter and U Creutzig",

year = "1996",

month = jul,

doi = "10.1007/s002770050193",

language = "English",

volume = "73",

pages = "11--24",

journal = "Annals of hematology",

issn = "0939-5555",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Therapy of childhood acute myelogenous leukemias

AU - Vormoor, J

AU - Boos, J

AU - Stahnke, K

AU - Jürgens, H

AU - Ritter, J

AU - Creutzig, U

PY - 1996/7

Y1 - 1996/7

N2 - Acute myelogenous leukemia (AML) accounts for approximately 20% of acute leukemias in children. Although AML is more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), significant progress in improving outcome for AML patients has been achieved over the past 15 years. This can be attributed to intensification of chemotherapy, increased use of bone marrow transplantation, and improved supportive care. Thus 30-50% of children with AML achieve long-term event-free survival with current treatment strategies [61, 66, 85, 96]. This review gives an overview about the evolution of and rationale for current pediatric treatment protocols, with special emphasis on the German Berlin-Frankfurt-Münster (BFM) studies, and discusses new directions for the future.

AB - Acute myelogenous leukemia (AML) accounts for approximately 20% of acute leukemias in children. Although AML is more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), significant progress in improving outcome for AML patients has been achieved over the past 15 years. This can be attributed to intensification of chemotherapy, increased use of bone marrow transplantation, and improved supportive care. Thus 30-50% of children with AML achieve long-term event-free survival with current treatment strategies [61, 66, 85, 96]. This review gives an overview about the evolution of and rationale for current pediatric treatment protocols, with special emphasis on the German Berlin-Frankfurt-Münster (BFM) studies, and discusses new directions for the future.

KW - Antineoplastic Agents/therapeutic use

KW - Bone Marrow Transplantation

KW - Central Nervous System Neoplasms/prevention & control

KW - Child

KW - Child, Preschool

KW - Clinical Trials as Topic

KW - Humans

KW - Infant

KW - Leukemia, Myeloid, Acute/therapy

KW - Prognosis

U2 - 10.1007/s002770050193

DO - 10.1007/s002770050193

M3 - Review article

C2 - 8695718

SN - 0939-5555

VL - 73

SP - 11

EP - 24

JO - Annals of hematology

JF - Annals of hematology

IS - 1

ER -

Therapy of childhood acute myelogenous leukemias

Abstract

Keywords

Access to Document

Fingerprint

Cite this